Abstract: The present disclosure discloses a method for synthesizing high-quality magnetic resonance images, wherein the method expands the value ranges of echo time TE and repetition time TR in a magnetic resonance signal formula to negative intervals, and expands the contribution of proton density PD to a negative power. The method can effectively reduce the influence of the measurement error of quantitative magnetic resonance imaging tissue parameters on the tissue contrast of the synthetic magnetic resonance image, and can obviously improve the tissue contrast of the synthetic magnetic resonance image. This method will significantly improve the imaging quality of synthetic magnetic resonance imaging, and promote its detection effect in neuroscience and clinical lesions. This method is expected to improve the imaging quality of synthetic magnetic resonance imaging and promote its detection effect in neuroscience and clinical lesions.

Abstract: The present invention relates to a branched peptide that includes a first peptide chain and a second peptide chain having its C-terminal amino acid covalently linked to a sidechain of an amino acid residue of the first peptide chain, wherein the first peptide chain includes a plurality of aromatic amino acids and, optionally, an aromatic group linked to an amino terminus of the first peptide chain; and the second peptide chain includes a plurality of hydrophilic amino acids and an enzyme cleavage site. Pharmaceutical compositions containing the branched peptide and one or more therapeutic agents in an aqueous medium are disclosed, where the branched peptides form micelle structures in the aqueous medium. Methods of using the pharmaceutical composition to deliver therapeutic agents, and for treating various disease conditions are also described.

Abstract: The present disclosure discloses a method for measuring relaxation time of ultrashort echo time magnetic resonance fingerprinting. In the method, semi-pulse excitation and semi-projection readout are adopted to shorten echo time (TE) to achieve acquisition of an ultrashort T2 time signal; and image acquisition and reconstruction are based on magnetic resonance fingerprint imaging technology. A TE change mode of sinusoidal fluctuation is introduced, so that distinguishing capability of a magnetic resonance fingerprint signal to short T2 and ultrashort T2 tissues is improved, and multi-parameter quantitative imaging of the short T2 and ultrashort T2 tissues and long T2 tissues is realized.

Abstract: The present invention relates to a branched peptide that includes a first peptide chain and a second peptide chain having its C-terminal amino acid covalently linked to a sidechain of an amino acid residue of the first peptide chain, wherein the first peptide chain includes a plurality of aromatic amino acids and, optionally, an aromatic group linked to an amino terminus of the first peptide chain; and the second peptide chain includes a plurality of hydrophilic amino acids and an enzyme cleavage site. Pharmaceutical compositions containing the branched peptide and one or more therapeutic agents in an aqueous medium are disclosed, where the branched peptides form micelle structures in the aqueous medium. Methods of using the pharmaceutical composition to deliver therapeutic agents, and for treating various disease conditions are also described.

Abstract: The present disclosure discloses a method for measuring relaxation time of ultrashort echo time magnetic resonance fingerprinting. In the method, semi-pulse excitation and semi-projection readout are adopted to shorten echo time (TE) to achieve acquisition of an ultrashort T2 time signal; and image acquisition and reconstruction are based on magnetic resonance fingerprint imaging technology. A TE change mode of sinusoidal fluctuation is introduced, so that distinguishing capability of a magnetic resonance fingerprint signal to short T2 and ultrashort T2 tissues is improved, and multi-parameter quantitative imaging of the short T2 and ultrashort T2 tissues and long T2 tissues is realized.

Abstract: The present invention relates to a branched peptide that includes a first peptide chain and a second peptide chain having its C-terminal amino acid covalently linked to a sidechain of an amino acid residue of the first peptide chain, wherein the first peptide chain includes a plurality of aromatic amino acids and, optionally, an aromatic group linked to an amino terminus of the first peptide chain; and the second peptide chain includes a plurality of hydrophilic amino acids and an enzyme cleavage site. Pharmaceutical compositions containing the branched peptide and one or more therapeutic agents in an aqueous medium are disclosed, where the branched peptides form micelle structures in the aqueous medium. Methods of using the pharmaceutical composition to deliver therapeutic agents, and for treating various disease conditions are also described.

Abstract: The present disclosure discloses a method for synthesizing high-quality magnetic resonance images, wherein the method expands the value ranges of echo time TE and repetition time TR in a magnetic resonance signal formula to negative intervals, and expands the contribution of proton density PD to a negative power. The method can effectively reduce the influence of the measurement error of quantitative magnetic resonance imaging tissue parameters on the tissue contrast of the synthetic magnetic resonance image, and can obviously improve the tissue contrast of the synthetic magnetic resonance image. This method will significantly improve the imaging quality of synthetic magnetic resonance imaging, and promote its detection effect in neuroscience and clinical lesions. This method is expected to improve the imaging quality of synthetic magnetic resonance imaging and promote its detection effect in neuroscience and clinical lesions.

Abstract: The present invention relates to a branched peptide that includes a first peptide chain and a second peptide chain having its C-terminal amino acid covalently linked to a sidechain of an amino acid residue of the first peptide chain, wherein the first peptide chain includes a plurality of aromatic amino acids and, optionally, an aromatic group linked to an amino terminus of the first peptide chain; and the second peptide chain includes a plurality of hydrophilic amino acids and an enzyme cleavage site. Pharmaceutical compositions containing the branched peptide and one or more therapeutic agents in an aqueous medium are disclosed, where the branched peptides form micelle structures in the aqueous medium. Methods of using the pharmaceutical composition to deliver therapeutic agents, and for treating various disease conditions are also described.